For those following Avian Influenza off medical site.
New vaccine against lethal avian influenza virus shows promise
Published: Wednesday, 3-May-2006
A commercially developed vaccine has successfully protected mice and ferrets
against a highly lethal avian influenza virus, according to the investigator
who led the study at St. Jude Children's Research Hospital.
The vaccine was developed by Vical Incorporated in San Diego, California.
This finding, coupled with results of previous studies that showed
protection against multiple human influenza strains, suggests that such a
vaccine would protect humans against multiple variants of the bird and human
influenza viruses, according to Richard Webby, Ph.D., assistant member of
Infectious Diseases at St. Jude. Such a vaccine could protect humans against
an H5N1 "bird flu" virus that mutates so that it adapts to humans and can
readily spread from person to person, Webby said. Flu experts and public
health officials fear that such an H5N1 variant would trigger a human
pandemic (worldwide epidemic).
Webby is scheduled to present the findings of this study at the U.S. Public
Health Service Professional Conference in Denver, Colo., May 3 at 12:30 pm
The investigators used two versions of Vical's multi-component, DNA-based
vaccine in the studies. One vaccine was directed against three viral
proteins: NP and M2, which are "conserved" proteins that generally do not
mutate quickly and therefore, are slow to avoid immune responses triggered
by the vaccine; and H5, a "variable" protein on the surface of the bird and
human flu viruses that is critical to their ability to infect cells. This
variable protein is known to mutate readily, thereby foiling previous immune
responses it triggered--whether due to natural exposure or vaccination. The
other version of the vaccine contained only the two conserved viral
In the St. Jude study, the full, three-component vaccine (H5, NP and M2)
provided complete protection in mice against lethal challenges with a highly
virulent (Vietnam/1203/2004) H5N1 avian influenza virus. Moreover, other
studies showed that a smaller version of the vaccine containing only the NP
and M2 components provided significant protection against several strains of
human influenza virus as well as the H5N1 "bird flu" strain.
"Such cross-protection against bird and human influenza is considered by
researchers to be the 'Holy Grail' of flu vaccines," Webby said. "By
stimulating immune responses against targets not likely to mutate, the
vaccine could trigger an immune defense against a broad range of variants of
"Even if the bird flu virus mutates so it becomes adapted to humans, this
kind of cross protection will allow the immune system to track and attack
such an emerging new variant without missing a beat," Webby said. "We
wouldn't have to wait to start developing a vaccine against it until after
the original virus mutated."
Webby's team showed that all mice and ferrets that received the DNA vaccine
survived the challenge with the virulent H5N1 strain, while those that
received a "blank" vaccine control did not survive. The vaccine also
prevented weight loss in all animals challenged with the virulent virus,
suggesting that the vaccine might also protect humans against serious
The studies included 16 mice or six ferrets in each vaccine or control
group. The DNA vaccines targeted NP and M2--with and without the H5 avian
influenza virus surface protein. All test DNA vaccines were formulated with
the company's Vaxfectin adjuvant. An adjuvant is an additive administered
with a vaccine that has little effect by itself, but improves the response
of the immune system to the vaccine.
To unsubscribe from this mailing list,
send the message:
(in the body of the message, with no Subject line)